



Attorney Docket No. 25822

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

MECKING et al.

Group Art Unit: 1615

Serial No.: 10/714,552

Examiner: Unknown

Filed: November 17, 2003

Title: **MEDICAL-TECHNOLOGY PRODUCT, PROCESS FOR ITS PRODUCTION,  
AND USE**

TRANSMITTAL LETTER

Commissioner of Patents  
P.O. Box 1450  
Alexandria, Va 22313-1450

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- (1) Transmittal Letter;
- (2) Supplemental Information Disclosure Statement;
- (3) International Search Report dated September 29, 2004;
- (4) PTO Form 1449 citing 2 references with 2 references attached.

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted,

**NATH & ASSOCIATES PLLC**

By: 

Gary M. Nath  
Registration No. 26,965  
Tanya E. Harkins  
Registration No. 52,993  
Customer No. 20529

Date: May 9, 2006  
NATH & ASSOCIATES PLLC  
112 South West Street  
Alexandria, VA 22314  
Phone: 703-548-6284  
Fax: 703-683-8396  
GMN/THE/dd:IDSupp\_ Transmittal.doc



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

MECKING et al.

Group Art Unit: 1615

Serial No.: 10/714,552

Examiner: Unknown

Filed: November 17, 2003

Title: **MEDICAL-TECHNOLOGY PRODUCT, PROCESS FOR ITS PRODUCTION,  
AND USE**INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars:

[NOTE: One only of items a, b, c, and d must be checked.]

- ☒ a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.
- ☐ b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.

The enclosed statement is accompanied by [check one]:

- ☐ i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or
- ☐ ii. a check in the amount required by 37 C.F.R. 1.17(p).
- ☐ c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311, but before payment of the issue fee.
- ☐ Certification report(e) below; and
- ☐ a check in the amount as required by 1.17(p).
- ☐ d. The enclosed statement is being filed pursuant to 37 C.F.R. 1.97(i), for placement in the file.
- ☐ e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

[ ] I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,

or

[ ] I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. '1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

[ ] Appropriate certification is attached.

[ X ] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

[ X ] g. Copies of the documents are attached herewith with a completed Form PTO-1449.

or

[ ] Copies of the documents are not attached as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:


[ ] or Copies of US Patents/Publications not attached as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.


Respectfully submitted,  
NATH & ASSOCIATES

By:

  
\_\_\_\_\_  
Gary M. Nath  
Registration No. 26,965  
Tanya E. Harkins  
Registration No. 52,993  
Customer No. 20529

Date: May 9, 2006

NATH & ASSOCIATES PLLC  
112 South West Street  
Alexandria, VA 22314  
Phone: 703-548-6284  
Fax: 703-683-8396  
GMN/TEH/dd (IDSupp\_Statement.DOC)

 <p style="margin-top: 10px;">FORM PTO-1449</p> <p style="margin-top: 10px;"><u>INFORMATION DISCLOSURE CITATION</u></p>				Atty Docket 25822		Serial No. 10/714,552	
				Applicant MECKING et al.			
				Filing Date November 17, 2003		Group Art Unit 1615	
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initial		Document Number	Issue Date	Name	Class	Sub- Class	Filing Date
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document Number	Date	Country	Class	Sub- Class	Trans- lation
	AG						
	AH						
	AI						
	AJ						
	AK						
<b>OTHER (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
	AL		Schierholz, J.M. et al., "Efficacy of Silver-coated medical devices", <u>Journal of Hospital Infection</u> , vol. 40, pp. 257-262, (1998).				
	AM		Aymonier, C. et al., "Hybrids of silver nanoparticles with amphiphilic hyperbranched macromolecules exhibiting antimicrobial properties", <u>Chemical Communications</u> , No. 24, pp. 3018-3019, XP001183146 (December 21, 2002).				
	AN						
Examiner				Date Considered			
<p>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609.</p> <p>Draw line through citation if not in conformance and not considered.</p> <p>Include copy of this form with next communication to Applicant.</p>							